N-hydroxy-N-(1-dibenzothien-3-ylethyl) urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: N-hydroxy-N-(1-dibenzothien-3-ylethyl) urea
• 英文别名: N-hydroxy-N-(1-dibenzothien-3-ylethyl)-urea；N-hydroxy-N-(1-dibenzothien-3-ylethyl)urea；1-(1-Dibenzothiophen-3-ylethyl)-1-hydroxyurea
• 化学式: C₁₅H₁₄N₂O₂S
• 分子量: 286.354
• InChiKey: CLNAEWGAMRPIGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  94.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  二苯并噻吩 生成 N-hydroxy-N-(1-dibenzothien-3-ylethyl) urea
  参考文献：
  名称：

  Dibenzofuran lipoxygenase inhibiting compounds, compositions and use

  摘要：

  该公式化合物为：##STR1## 其中 R.sub.1 为 (1) 氢，(2) C.sub.1 到 C.sub.4 烷基，(3) C.sub.2 到 C.sub.4 烯基，或 (4) NR.sub.2 R.sub.3，其中 R.sub.2 和 R.sub.3 独立选择自氢，C.sub.1 到 C.sub.4 烷基和羟基，但 R.sub.2 和 R.sub.3 不同时为羟基；X 为 (1) 氧，(2) 硫，(3) SO.sub.2，或 (4) NR.sub.4，其中 R.sub.4 为 (1) 氢，(2) C.sub.1 到 C.sub.6 烷基，(3) C.sub.1 到 C.sub.6 烷酰基或 (4) 芳酰基；A 选择自 C.sub.1 到 C.sub.6 烷基和 C.sub.2 到 C.sub.6 烯基；n 为 0-4；Y 在每次出现时独立选择自 (1) 氢，(2) 卤素，(3) 羟基，(4) 氰基，(5) 卤代烷基，(6) C.sub.1 到 C.sub.12 烷基，(7) C.sub.2 到 C.sub.12 烯基，(8) C.sub.1 到 C.sub.12 烷氧基，(9) C.sub.3 到 C.sub.8 环烷基，(10) 芳基，(11) 芳氧基，(12) 芳酰基，(13) C.sub.1 到 C.sub.12 芳基烷基，(14) C.sub.2 到 C.sub.12 芳基烯基，(15) C.sub.1 到 C.sub.12 芳基氧基，(16) C.sub.1 到 C.sub.12 芳基硫基氧基，和取代衍生物 fo (17) 芳基，(18) 芳氧基，(19) 芳酰基，(20) C.sub.1 到 C.sub.12 芳基烷基，(21) C.sub.2 到 C.sub.12 芳基烯基，(22) C.sub.1 到 C.sub.12 芳基氧基，或 (23) C.sub.1 到 C.sub.12 芳基硫基氧基，其中取代基选择自卤素，硝基，氰基，C.sub.1 到 C.sub.12 烷基，烷氧基和卤代烷基；M 为氢，药用可接受阳离子，芳酰基，或 C.sub.1 到 C.sub.12，烷酰基是 5- 和/或 12- 脂氧化酶酶的有效抑制剂。还公开了抑制脂氧化酶的组合物和抑制脂氧化酶的方法。

  公开号：

  US04769387A1

文献信息

• Tricyclic lipoxygenase inhibiting compounds
  申请人：ABBOTT LABORATORIES

  公开号：EP0346939A1

  公开（公告）日：1989-12-20

  Compounds of the formula: wherein R1 is hydrogen, C1 to C4 alkyl, C2 to C4 alkenyl, or NR2R3, wherein R2 and R3 are independently selected from hydrogen, C1 to C4 alkyl and hydroxyl, but R2 and R3 are not simultanecusly hydroxyl; X is oxygen, sulfur, SO2, or NR4, wherein R4 is hydrogen, C1 to C6 alkyl, C1 to C6 alkoyl or aroyl; A is selected from C1 to C6 alkylene and C2 to C6 alkenylene; Y is selected independently at each occurrence from hydrogen, halogen, hydroxy, cyano, nitro, halosubstituted alkyl, C1 to C12 alkyl, C2 to C12 alkenyl, C1 to C12 alkoxy, C3 to C8 cycloalkyl, aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, C1 to C12 arylthioalkoxy, and substituted derivatives of aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, or C1 to C12 arylthioalkoxy, wherein C12 alkyl, alkoxy, and halosubstituted alkyl; n is a number having the values 0-4; when n = 0 then Y = hydrogen; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C1 to C12 alkoyl. These compounds are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method of inhibiting lipoxygenase.

  式中的化合物： 其中 R1 是氢、C1 至 C4 烷基、C2 至 C4 烯基或 NR2R3，其中 R2 和 R3 独立选自氢、C1 至 C4 烷基和羟基，但 R2 和 R3 不同时是羟基； X 是氧、硫、SO2 或 NR4，其中 R4 是氢、C1 至 C6 烷基、C1 至 C6 烷酰基或芳基； A 选自 C1 至 C6 亚烷基和 C2 至 C6 烯基； C1 至 C12 芳烷氧基、C1 至 C12 芳硫基烷氧基，以及芳基、芳氧基、芳烷基、C1 至 C12 芳烷基、C2 至 C12 芳烯基、C1 至 C12 芳烷氧基或 C1 至 C12 芳硫基烷氧基的取代衍生物，其中 C12 烷基、烷氧基和卤代烷基；n 是数值为 0-4 的数字；当 n = 0 时，Y = 氢； M 是氢、药学上可接受的阳离子、芳基或 C1 至 C12 烷酰基。这些化合物是 5-和/或 12-脂氧合酶的强效抑制剂。还公开了抑制脂氧合酶的组合物和抑制脂氧合酶的方法。
• US4769387A
  申请人：——

  公开号：US4769387A

  公开（公告）日：1988-09-06
• US4822811A
  申请人：——

  公开号：US4822811A

  公开（公告）日：1989-04-18
• Dibenzofuran lipoxygenase inhibiting compounds, compositions and use
  申请人：Abbott Laboratories

  公开号：US04769387A1

  公开（公告）日：1988-09-06

  Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from hydrogen, C.sub.1 to C.sub.4 alkyl and hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl; X is (1) oxygen, (2) sulfur, (3) SO.sub.2, or (4) NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkoyl or (4) aroyl; A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene; n is 0-4; Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) aryl, (11) aryloxy, (12) aroyl, (13) C.sub.1 to C.sub.12 arylalkyl, (14) C.sub.2 to C.sub.12 arylalkenyl, (15) C.sub.1 to C.sub.12 arylalkoxy, (16) C.sub.1 to C.sub.12 arylthioalkoxy, and substituted derivatives fo (17) aryl, (18) aryloxy, (19) aroyl, (20) C.sub.1 to C.sub.12 arylalkyl, (21) C.sub.2 to C.sub.12 arylalkenyl, (22) C.sub.1 to C.sub.12 arylalkoxy, or (23) C.sub.1 to C.sub.12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and halosubstituted alkyl; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12, alkoyl are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method of inhibiting lipoxygenase.

  该公式化合物为：##STR1## 其中 R.sub.1 为 (1) 氢，(2) C.sub.1 到 C.sub.4 烷基，(3) C.sub.2 到 C.sub.4 烯基，或 (4) NR.sub.2 R.sub.3，其中 R.sub.2 和 R.sub.3 独立选择自氢，C.sub.1 到 C.sub.4 烷基和羟基，但 R.sub.2 和 R.sub.3 不同时为羟基；X 为 (1) 氧，(2) 硫，(3) SO.sub.2，或 (4) NR.sub.4，其中 R.sub.4 为 (1) 氢，(2) C.sub.1 到 C.sub.6 烷基，(3) C.sub.1 到 C.sub.6 烷酰基或 (4) 芳酰基；A 选择自 C.sub.1 到 C.sub.6 烷基和 C.sub.2 到 C.sub.6 烯基；n 为 0-4；Y 在每次出现时独立选择自 (1) 氢，(2) 卤素，(3) 羟基，(4) 氰基，(5) 卤代烷基，(6) C.sub.1 到 C.sub.12 烷基，(7) C.sub.2 到 C.sub.12 烯基，(8) C.sub.1 到 C.sub.12 烷氧基，(9) C.sub.3 到 C.sub.8 环烷基，(10) 芳基，(11) 芳氧基，(12) 芳酰基，(13) C.sub.1 到 C.sub.12 芳基烷基，(14) C.sub.2 到 C.sub.12 芳基烯基，(15) C.sub.1 到 C.sub.12 芳基氧基，(16) C.sub.1 到 C.sub.12 芳基硫基氧基，和取代衍生物 fo (17) 芳基，(18) 芳氧基，(19) 芳酰基，(20) C.sub.1 到 C.sub.12 芳基烷基，(21) C.sub.2 到 C.sub.12 芳基烯基，(22) C.sub.1 到 C.sub.12 芳基氧基，或 (23) C.sub.1 到 C.sub.12 芳基硫基氧基，其中取代基选择自卤素，硝基，氰基，C.sub.1 到 C.sub.12 烷基，烷氧基和卤代烷基；M 为氢，药用可接受阳离子，芳酰基，或 C.sub.1 到 C.sub.12，烷酰基是 5- 和/或 12- 脂氧化酶酶的有效抑制剂。还公开了抑制脂氧化酶的组合物和抑制脂氧化酶的方法。